奇正藏藥(002287.SZ)連續第7日漲停 收深交所關注函
格隆匯8月4日丨奇正藏藥(002287.SZ)今日再度漲停,報45.23元,逼近2016年11月創出的歷史最高價47.66元,暫成交2.98億元,最新總市值240億元。深交所昨日向六連板奇正藏藥下發關注函,要求説明公司基本面是否發生重大變化,是否存在應披露而未披露的重大信息,業績快報是否存在需要更正、補充之處;是否已向控股股東或實際控制人等書面函詢,説明其是否計劃對公司進行股權轉讓、資產重組以及其他處於籌劃階段的重大事項。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.